...
首页> 外文期刊>Radiation oncology >Implementation, adherence, and results of systematic SARS-CoV-2 testing for asymptomatic patients treated at a tertiary care regional radiation oncology network
【24h】

Implementation, adherence, and results of systematic SARS-CoV-2 testing for asymptomatic patients treated at a tertiary care regional radiation oncology network

机译:系统SARS-COV-2对大专院区辐射肿瘤网络治疗的无症状患者进行系统SARS-COV-2测试的实施,依从性和结果

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus is a current pandemic. We initiated a program of systematic SARS-CoV-2 polymerase chain reaction (PCR) testing in all asymptomatic patients receiving radiotherapy (RT) at a large radiation oncology network in the Charlotte, NC metropolitan region and report adherence and results of the testing program. Patients undergoing simulation for RT between May 18, 2020 and July 10, 2020 within the Levine Cancer Institute radiation oncology network who were asymptomatic for COVID-19 associated symptoms, without previous positive SARS-CoV-2 testing, and without recent high-risk contacts were included. PCR testing was performed on nasal cavity or nasopharyngeal swab samples. Testing was performed within 2?weeks of RT start (pre-RT) and at least every 4?weeks during RT for patients with prolonged RT courses (intra-RT). An automated task based process using the oncology electronic medical record (EMR) was developed specifically for this purpose. A total of 604 unique patients were included in the cohort. Details on testing workflow and implementation are described herein. Pre-RT PCR testing was performed in 573 (94.9%) patients, of which 4 (0.7%) were positive. The adherence rate to intra-RT testing overall was 91.6%. Four additional patients (0.7%) tested positive during their RT course, of whom 3 were tested due to symptom development and 1 was asymptomatic and identified via systematic testing. A total of 8 (1.3%) patients tested positive overall. There were no known cases of SARS-CoV-2 transmission from infected patients to clinic staff and/or other patients. We detailed the workflows used to implement systematic SARS-CoV-2 for asymptomatic patients at a large radiation oncology network. Adherence rates for pre-RT and intra-RT testing were high using this process. This information allowed for appropriate delay in initiating RT, minimizing the occurrence of RT treatment interruptions, and no known cases of transmission from infected patients to clinic staff and/or other patients.
机译:由SARS-COV-2病毒引起的冠状病毒疾病2019(Covid-19)是目前的大流行病。我们在夏洛特,NC大都市区的大型辐射肿瘤网络中接受放射疗法(RT)的所有无症状患者中的系统SARS-COV-2聚合酶链反应(PCR)检测开始了一份系统的SARS-COV-2聚合酶链反应(PCR)测试。在5月18日至7月10日至7月10日之间进行模拟的患者,在Levine癌症研究所放射肿瘤学网络中,对于Covid-19相关症状无症状,没有先前的SARS-COV-2测试,并且没有最近的高风险接触包括在内。在鼻腔或鼻咽拭子样品上进行PCR测试。在RT开始(预RT)的2个时间内进行测试,至少每4周内进行一次RT,延长RT课程的患者(intra-RT)。使用肿瘤学电子医疗记录(EMR)的基于自动任务的过程是专门为此开发的。共队共用了604名独特的患者。本文描述了测试工作流程和实现的详细信息。在573(94.9%)患者中进行RT PCR测试,其中4(0.7%)为阳性。对RT测试的粘附率总体上为91.6%。在其RT过程中进行了四种额外的患者(0.7%),其中3个由于症状发育而测试3,并且1是无症状的,通过系统测试鉴定。总共8名(1.3%)患者的患者整体测试了正面。没有已知的SARS-COV-2从感染患者到诊所员工和/或其他患者的SARS-COV-2传播情况。我们详细介绍了用于在大型辐射肿瘤网络中对无症状患者实施系统SARS-COV-2的工作流程。使用该过程高RT和RT测试的粘附速率高。该信息允许适当的延迟启动RT,最大限度地减少RT处理中断的发生,并且没有已知从感染患者到诊所员工和/或其他患者的传播情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号